Jessie Yanxiang Guo
Assistant Professor
Department: Department of Medicine
Phone: 1.7322359657
Email: yanxiang@cinj.rutgers.edu
Robert Wood Johnson Medical School
The Cancer Institute of NJ, Room 3039
195 Little Albany Street
New Brunswick, NJ 08901
Key Words: Cancer metabolism, autophagy, oncogenes, cancer metastasis, metabolomics, lung cancer therapy
Lab Site URL

Research in the Guo Lab focuses on the field of cancer metabolism, with an emphasis on how autophagy is involved in modulating Ras-driven cancer metabolism to maintain Kras-driven lung tumor growth and metastasis. Ras-driven lung cancers are among the most lethal, and unfortunately, efforts to develop drugs that target Ras directly have so far been unsuccessful. It has been known for decades that the metabolism of cancer cells is distinct from that of normal cells, suggesting that targeting metabolism is a valuable approach to cancer therapy. Autophagy is a process that cell eats itself to maintain cellular metabolism during metabolic stress. Previous research from Dr. Guo and others demonstrated that autophagy is required to maintain functional mitochondria to support Kras-driven Non-small cell lung cancer (NSCLC), which suggests that targeting autophagy or mitochondria could be potential therapy for Ras-driven cancer. Dr. Guo’s research program will further understand the mechanisms by which autophagy regulates mitochondrial metabolism in Kras-driven cancers and enable the evaluation of the potential for autophagy inhibition to enhance cancer therapy. Additionally, tumor metastasis is the major cause of mortality for NSCLC patients, Dr. Guo will examine if autophagy is required to maintain metabolism necessary for NSCLC metastasis. Combination of genetically engineered mouse models and the state-of-the-art metabolomic and lipidomic analysis will be utilized to achieve these goals. Knowledge gained from this research program will not only increase our understanding of the regulation of autophagy in Kras-driven lung cancer metabolism, but may uncover novel drug targets for lung cancer.